Expected characteristics of an ideal, all-purpose inhaled corticosteroid for the treatment of XXXX .

@entity1 @entity137 @entity4738 @entity565 @entity16179
BACKGROUND: Inhaled corticosteroids (ICSs) are well established as the mainstay of @entity565 therapy. A number of ICSs are now available, each with unique pharmacokinetic/pharmacodynamic profiles and physical characteristics. OBJECTIVE: This article reviews the key characteristics of an ideal @entity16179 and uses examples of existing agents to indicate the extent to which therapies reach these goals. RESULTS: Improved therapeutic efficacy in an @entity16179 may be offset by an increase in systemic effects. The ideal characteristics of an @entity16179 include optimal clinical efficacy and no @entity137 in combination with a convenient and easy-to-use inhaler device. To achieve this optimal profile, an @entity16179 should have the following: a high affinity for and potency at the @entity4738 ; prolonged retention in the lung; minimal or no oral bioavailability (ie, high first-pass inactivation); and rapid, complete systemic inactivation. The formulation and type of inhaler device are also important considerations: they should provide deposition in the lung in both large and small airways with no absorption effects outside the lung. ICSs should be evaluated for administration with several different delivery devices to ensure ease of use by @entity1 of all ages with different @entity565 severities. An @entity16179 that can be administered QD is also likely to improve @entity1 adherence by simplifying the treatment regimen. CONCLUSION: An ideal @entity16179 should have a large therapeutic margin, be used safely and effectively for long periods, be administered QD, be suitable for use in @entity1 of all ages and @entity565 severities, and offer both control and prevention of @entity565 symptoms and exacerbations.
